HRP20191607T1 - Biomarkeri za inaktivaciju kolateralnih gena i ciljevi za terapiju raka - Google Patents

Biomarkeri za inaktivaciju kolateralnih gena i ciljevi za terapiju raka Download PDF

Info

Publication number
HRP20191607T1
HRP20191607T1 HRP20191607T HRP20191607T1 HR P20191607 T1 HRP20191607 T1 HR P20191607T1 HR P20191607 T HRP20191607 T HR P20191607T HR P20191607 T1 HRP20191607 T1 HR P20191607T1
Authority
HR
Croatia
Prior art keywords
redundant
homolog
host gene
redundant homolog
cancer
Prior art date
Application number
Other languages
English (en)
Inventor
Florian L Muller
Eliot Fletcher-Sananikone
Simona Colla
Elisa Aquilanti
Ronald Depinho
Original Assignee
Univ Texas
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Dana Farber Cancer Inst Inc filed Critical Univ Texas
Publication of HRP20191607T1 publication Critical patent/HRP20191607T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01001—Carbonate dehydratase (4.2.1.1), i.e. carbonic anhydrase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)

Claims (4)

1. Pripravak namijenjen uporabi u liječenju raka u subjekta, gdje rak ima homozigotnu deleciju u domaćinskom genu i domaćinski gen ima funkcionalno redundantni homolog, pripravak sadrži inhibitor redundantnog homologa u količini dovoljnoj da inhibira aktivnost redundantnog homologa, pri čemu je domaćinski gen enolaza 1 (ENO1), redundantni homolog je endolaza 2 (ENO2) i inhibitor je nukleinska kiselina koja sprječava ekspresiju ili aktivnost redundantnog homologa, antitijelo koje specifično veže redundantni homolog, fosfonoacetohidroksamat, poželjno nadalje sadrži kemoterapeutski agens, pri čemu kemoterapeutski agens poželjno međudjeluje s DNA homeostazom.
2. Pripravak namijenjen uporabi u liječenju raka u subjekta, gdje rak ima homozigotnu deleciju u domaćinskom genu i domaćinski gen ima funkcionalno redundantni homolog, pripravak sadrži inhibitor redundantnog homologa u količini dovoljnoj da inhibira aktivnost redundantnog homologa, pri čemu je domaćinski gen heksoza-6-fosfata dehidrogenaza (H6PD), redundantni homolog je glukoza-6 dehidrogenaza (G6PD) a inhibitor je nukleinska kiselina koja inhibira ekspresiju ili aktivnost redundantnog homologa, antitijelo koje specifično veže redundantni homolog, dehidroepiandrosteron, poželjno nadalje sadrži kemoterapeutski agens, pri čemu kemoterapeutski agens poželjno međudjeluje s DNA homeostazom.
3. Pripravak namijenjen uporabi u liječenju raka u subjekta, gdje rak ima homozigotnu deleciju u domaćinskom genu i domaćinski gen ima funkcionalno redundantni homolog, pripravak sadrži inhibitor redundantnog homologa u količini dovoljnoj da inhibira aktivnost redundantnog homologa, pri čemu je domaćinski gen Nikotinamid nukleotid adenilil transferaza 1 (NMNAT1), redundantni homolog je Nikotinamid nukleotid adenilil transferaza 2 (NMNAT2) ili nikotinamid nukleotid adenilil transferaza 3 (NMNAT3) a inhibitor je nukleinska kiselina koja inhibira ekspresiju ili aktivnost redundantnog homologa, antitijelo koje specifično veže redundantni homolog, Np2AD, Np4AD ili Nap4AD, poželjno nadalje sadrži kemoterapeutski agens, pri čemu kemoterapeutski agens poželjno međudjeluje s DNA homeostazom.
4. Pripravak namijenjen uporabi u liječenju raka u subjekta, gdje rak ima homozigotnu deleciju u domaćinskom genu i domaćinskom genu ima funkcionalno redundantni homolog, pripravak sadrži inhibitor redundantnog homologa u količini dovoljnoj da inhibira aktivnost redundantnog homologa, pri čemu (a) domaćinski gen je član porodice kinezin 1B (KIF1B) i redundantni homolog je član porodice kinezin 1A (KIF1A) ili član porodice kinezin 1C (KIF1C); ili (b) domaćinski gen je faktor ubikvitinacije E4B (UBE4B) i redundantni homolog je faktor ubikvitinacije 4A (UBE4A); a inhibitor je nukleinska kiselina koja inhibira ekspresiju ili aktivnost redundantnog homologa ili antitijela koje specifično veže redundantni homolog, poželjno nadalje sadrži kemoterapeutski agens, pri čemu kemoterapeutski agens poželjno međudjeluje s DNA homeostazom.
HRP20191607 2011-12-14 2019-09-05 Biomarkeri za inaktivaciju kolateralnih gena i ciljevi za terapiju raka HRP20191607T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161570366P 2011-12-14 2011-12-14
US201261652738P 2012-05-29 2012-05-29
EP12858619.5A EP2790738B1 (en) 2011-12-14 2012-12-14 Collateral gene inactivation biomarkers and targets for cancer therapy
PCT/US2012/069767 WO2013090732A2 (en) 2011-12-14 2012-12-14 Collateral gene inactivation biomarkers and targets for cancer therapy

Publications (1)

Publication Number Publication Date
HRP20191607T1 true HRP20191607T1 (hr) 2019-12-13

Family

ID=48613367

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191607 HRP20191607T1 (hr) 2011-12-14 2019-09-05 Biomarkeri za inaktivaciju kolateralnih gena i ciljevi za terapiju raka

Country Status (11)

Country Link
US (1) US9452182B2 (hr)
EP (2) EP3603678A3 (hr)
JP (2) JP6820653B2 (hr)
KR (2) KR102144452B1 (hr)
CN (3) CN104144707B (hr)
DK (1) DK2790738T3 (hr)
ES (1) ES2746058T3 (hr)
HR (1) HRP20191607T1 (hr)
HU (1) HUE045359T2 (hr)
IN (1) IN2014DN05803A (hr)
WO (1) WO2013090732A2 (hr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10188707B2 (en) 2014-01-13 2019-01-29 Berg, LLC Enolase 1 (Eno1) compositions and uses thereof
CN104894229A (zh) * 2014-03-04 2015-09-09 中南大学 己糖激酶2作为鼻咽癌放疗预后预测的生物标志物
RU2761662C2 (ru) * 2014-12-31 2021-12-13 Девелопмент Сентер Фор Байотекнолоджи Гуманизированные антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой терапии
PT3268376T (pt) 2015-03-09 2022-04-08 Univ Texas Inibidores de enolase e métodos de tratamento com os mesmos
US11492670B2 (en) 2015-10-27 2022-11-08 The Broad Institute Inc. Compositions and methods for targeting cancer-specific sequence variations
CA2937896A1 (en) * 2016-08-02 2018-02-02 Universite De Montreal Use of mubritinib for the treatment of poor prognosis acute myeloid leukemia
CN107217054B (zh) * 2017-04-25 2020-08-14 中山大学肿瘤防治中心 G6pd基因及其表达产物在治疗结直肠癌中的应用
CN107460250B (zh) * 2017-09-28 2020-07-28 郑州大学第一附属医院 基于kif14、kif15和kif20a基因的透明细胞肾癌诊断试剂盒及其使用方法
BR112021019376A2 (pt) * 2019-03-29 2021-12-07 Univ Texas Compostos com atividade antitumor contra células cancerígenas transportando inserções de éxon 21 de her2
US20220244263A1 (en) * 2019-05-28 2022-08-04 The Regents Of The University Of California Methods for treating small cell neuroendocrine and related cancers
WO2021150925A1 (en) * 2020-01-24 2021-07-29 Dana-Farber Cancer Institute, Inc. Uses of biomarkers for improving immunotherapy
CN113567675B (zh) * 2020-04-28 2023-09-22 苏州浚惠生物科技有限公司 用于肿瘤的己糖激酶2抑制剂液体活检伴随诊断和试剂盒
CA3195040A1 (en) * 2020-10-06 2022-04-14 Matthias W. Hentze Screening method for the identification of novel therapeutic compounds
WO2023089032A1 (en) * 2021-11-19 2023-05-25 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
WO2023239958A1 (en) * 2022-06-10 2023-12-14 The Children's Hospital Of Philadelphia Alternatively spliced isoform in cancer and methods of use thereof
CN114751961B (zh) * 2022-06-14 2022-09-20 中山大学孙逸仙纪念医院 circ0005199-173aa蛋白及其在制备食管癌诊断产品中的应用
CN115074445B (zh) * 2022-08-09 2023-08-08 河北医科大学第二医院 Eno3在肾癌诊断及治疗中的应用
CN115825308B (zh) * 2022-11-30 2023-06-09 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) 鼻咽癌相关尿液标志物在制备用于鼻咽癌诊断/预后的产品中的应用
CN116286828B (zh) * 2023-05-12 2023-08-18 中国人民解放军军事科学院军事医学研究院 一种寡聚核酸siRNA及其在制备用于预防和治疗肝癌的药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5279721A (en) 1993-04-22 1994-01-18 Peter Schmid Apparatus and method for an automated electrophoresis system
AU6764398A (en) * 1997-03-20 1998-10-12 Variagenics, Inc. Target genes for allele-specific drugs
US6046002A (en) 1998-01-05 2000-04-04 The Board Of Trustees Of The Leland Stanford Junior University Highly parallel and sensitive method for identifying drugs and drug targets
US6200754B1 (en) * 1998-03-19 2001-03-13 Variagenics, Inc. Inhibitors of alternative alleles of genes encoding products that mediate cell response to environmental changes
ATE408593T1 (de) 2001-05-03 2008-10-15 Galileo Lab Inc Pyruvatderivate
AU2003220201A1 (en) * 2002-03-26 2003-10-13 Indiana University Purification and cloning of nmn adenylyltranserase and its therapeutic use
DE602005014651D1 (de) * 2004-08-30 2009-07-09 Interstitial Therapeutics Medizinischer stent mit atp-synthesehemmern
JP5109131B2 (ja) 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
WO2007072219A2 (en) * 2005-09-21 2007-06-28 Aurelium Biopharma Inc. Alpha enolase-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance
US8193238B2 (en) 2006-03-08 2012-06-05 University Of Maryland, Baltimore Inhibition of microtubule protrusion in cancer cells
JP2010516227A (ja) * 2006-11-02 2010-05-20 ホワン，ラン ユビキチン関連の酵素との相互作用を破壊するための阻害剤及びその応用
TWI610939B (zh) 2007-02-21 2018-01-11 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
WO2009002607A1 (en) * 2007-05-01 2008-12-31 Dana-Farber Cancer Institute, Inc. Compositions and methods for identifying transforming and tumor suppressor genes
CN102225201A (zh) * 2010-05-11 2011-10-26 中国医学科学院基础医学研究所 糖酵解抑制剂的新用途

Also Published As

Publication number Publication date
JP2015504041A (ja) 2015-02-05
JP2019011365A (ja) 2019-01-24
HUE045359T2 (hu) 2019-12-30
EP2790738A2 (en) 2014-10-22
WO2013090732A3 (en) 2013-09-26
JP7193296B2 (ja) 2022-12-20
CN109276717A (zh) 2019-01-29
CN104144707A (zh) 2014-11-12
IN2014DN05803A (hr) 2015-05-15
CN109276717B (zh) 2022-04-12
DK2790738T3 (da) 2019-08-26
EP3603678A2 (en) 2020-02-05
KR20140128299A (ko) 2014-11-05
EP2790738B1 (en) 2019-08-14
CN104144707B (zh) 2018-09-14
US20140378529A1 (en) 2014-12-25
US9452182B2 (en) 2016-09-27
WO2013090732A2 (en) 2013-06-20
CN115177727A (zh) 2022-10-14
EP2790738A4 (en) 2015-12-30
JP6820653B2 (ja) 2021-01-27
KR102355121B1 (ko) 2022-02-09
EP3603678A3 (en) 2020-07-29
KR20200100197A (ko) 2020-08-25
ES2746058T3 (es) 2020-03-04
KR102144452B1 (ko) 2020-08-18

Similar Documents

Publication Publication Date Title
HRP20191607T1 (hr) Biomarkeri za inaktivaciju kolateralnih gena i ciljevi za terapiju raka
Amabile et al. Inheritable silencing of endogenous genes by hit-and-run targeted epigenetic editing
Liu et al. Regulation of microRNAs by epigenetics and their interplay involved in cancer
Kukreja et al. MicroRNAs: new players in cardiac injury and protection
BR112021019793A2 (pt) Composições e métodos para inibir expressão de gene no sistema nervoso central
Delas et al. lncRNA requirements for mouse acute myeloid leukemia and normal differentiation
HRP20211706T1 (hr) Nukleazom posredovana regulacija ekspresije gena
Dryhurst et al. Histone H2A. Z prepares the prostate specific antigen (PSA) gene for androgen receptor-mediated transcription and is upregulated in a model of prostate cancer progression
Yu et al. Epigenetic drugs can stimulate metastasis through enhanced expression of the pro-metastatic Ezrin gene
Song et al. miR‐483 inhibits bovine myoblast cell proliferation and differentiation via IGF1/PI3K/AKT signal pathway
AR084319A1 (es) INHIBIDORES DE microARN (miARN O miR) QUE COMPRENDEN NUCLEOTIDOS BLOQUEADOS
Lettieri-Barbato et al. MicroRNAs, long non-coding RNAs, and circular RNAs in the redox control of cell senescence
Zheng et al. RNA activation: promise as a new weapon against cancer
NZ627372A (en) Clostridium histolyticum enzymes and methods for the use thereof
Zhang et al. The biological function and potential mechanism of long non‐coding RNAs in cardiovascular disease
BR112014032239A2 (pt) inibidores da família de mir-15 de micro-rnas
Wang et al. Potential roles of telomeres and telomerase in neurodegenerative diseases
Yuan et al. An oncolytic adenovirus expressing SNORD44 and GAS5 exhibits antitumor effect in colorectal cancer cells
Yuan et al. miR‑195 promotes LPS‑mediated intestinal epithelial cell apoptosis via targeting SIRT1/eIF2a
JP2019534298A5 (hr)
Dong et al. HOXA10-AS: a novel oncogenic long non-coding RNA in glioma
Miao et al. CircUSP36 knockdown alleviates oxidized low‑density lipoprotein‑induced cell injury and inflammatory responses in human umbilical vein endothelial cells via the miR‑20a‑5p/ROCK2 axis
Chen et al. MicroRNA-132 targeting PTEN contributes to cilostazol-promoted vascular smooth muscle cell differentiation
WO2011071535A3 (en) Compositions and methods for inhibiting human host cell factors required for influenza virus replication
BR112013004948A2 (pt) intensificador viral baciliforme de cana de açúcar (scbv) e seu uso na genômica funcional de plantas